Sai Life Sciences IPO
Historical offer record. This offer is closed for applications. Prices and subscriptions describe the past offer; GMP observations are unofficial past records, not current quotes or listing predictions.
Data provider: FinAPI. This is a third-party summary, not an official prospectus. Read our data limitations and editorial policy.
No GMP observations are available for this historical offer record. No premium or listing-gain estimate is shown.
Price band
₹522 – ₹549
Lot size
27 shares
Offer application amount
₹14,823
Issue size
₹3042.62 Cr
Historical offer amount for 1 lot at the upper issue price. Confirm the lot size and application terms in the issuer prospectus.
Reported IPO schedule
| Open date | 11 Dec 2024 |
| Close date | 13 Dec 2024 |
| Allotment finalisation | 16 Dec 2024 |
| Refund initiation | 17 Dec 2024 |
| Shares credited to demat | 17 Dec 2024 |
| Reported listing date | 18 Dec 2024 |
Issue size
About Sai Life Sciences
Established in January 1999, Sai Life Science Limited works with innovative pharma and biotech companies by providing services across drug discovery, development, and manufacturing of small-molecule new chemical entities (NCE). Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRDMO). The company uses its scientific knowledge and skills to deal with critical healthcare challenges. In the future, they aim to develop medicines to treat conditions that are not curable right now and make a huge difference in the future of healthcare. Their services can be customized according to the customer’s needs, whether it’s a small client, a large biotech company, or a global pharmaceutical company making them adaptable and unstoppable. They are growing more in CRDMO than their competitors by earning revenue CAGR (Compound Annual Growth Rate) and EBITDA CAGR from fiscal year 2022 to 2024. They have always delivered a wide set of NCE development programs for their customers over the past 24 years. Quality, price, and responsiveness are the main 3 key areas where they have shown incredible value to its clients.
Company summary supplied by FinAPI. Read the prospectus for the issuer's disclosures and audited financials.
Offer documents and primary references
Read the issuer's offer document and any corrigenda for the full disclosures. A third-party details page is a summary; SEBI filing access does not imply an endorsement of the offer or this website.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.